

Can Latency-Reversing Drugs Reawaken Dormant Retrovirus Infection? A Mathematical Analysis

S. Chen Rheast LLC, 1331 Lamar St, Houston, TX 77010, USA. chen@rheast.com

Abstract

The technique of using drugs to target latent virus reservoir has been introduced to reawaken the dormant virus so that the immune system can attack it. However, further tests have shown this method to fail in laboratory tests. In this work, the author tries to mathematically analyze whether drugs can be used to reawaken dormant virus reservoirs. The study uses mathematical formulas to differentiate between different relationship types between sets of elements, and then a model of protein reawakening dormant reservoirs is presented. The results show that the amino acid sequences ARG of gag proteins of HTLV1, HTLV2, STLV1 and STLV2 match with their primer binding site GGGGGCTCG in the 3'-to-5' direction, and the amino acid sequences SPR of gag proteins of HIV1, HIV2, SIV and FIV match with their primer binding site GGCGCCCGA in the 3'-to-5' direction. The gag, gag-pol and gag-pro-pol proteins are promising for reawakening dormant retrovirus infection. The author hence believes that the latency-reversing drugs were involved in the process of transcription of cancer, and the genome they reawakened just happened to contain the genome of the retrovirus, which means that it was false reawakening. On the other hand, using proteins of retroviruses to reawaken them is more reliable, just like androgen receptor activates the *IGF1R* gene.

1. Introduction

The acquired immunodeficiency syndrome (AIDS) is a disease caused by the human immunodeficiency virus (HIV). The virus attacks immune system cells in the body to use their machinery to make copies of itself. However, some HIV-infected immune cells enter a state in which they do not produce new virus, called the resting or latent state. These form latent HIV reservoir, in which HIV can hide for years, avoiding HIV therapy. At any time, these cells can become active again and start to make more copies of the virus [1]. Scientists have used this opportunity to develop methods to target these latent reservoirs and make them active, so that they can be identified and targeted by HIV therapy. However, scientists at Johns Hopkins reported that compounds they hoped would 'wake up' dormant reservoirs of HIV inside the immune system. T cells have failed to do so in laboratory tests on white blood cells taken directly from patients infected with HIV [2]. Hence more investigation is needed to decide on the applicability of this method. In this article, the author tries to mathematically analyze whether latency-reversing drugs can reawaken the sleeping retrovirus.

2. Methods

2.1. Differentiating between the contain and equal relationships

The study designed an experiment as follows. First, the author prepares several T cells and the HIV1 double-stranded DNA, which are converted by reverse transcription. HIV genome contains at least nine genes, such as gag, pol and env [3]. The *IGF1R* gene is located on the human chromosome 15, which contains at least 21 exons, such as ENSE00003838363 and ENSE00001316091 [4]. In mathematics, a set is a collection of elements, so the genome can be defined as a set of elements, by listing its elements between curly brackets, separated by commas:

$$H = \{\text{gag, pol, env}\} \quad I = \{\text{ENSE00003838363, ENSE00001316091}\}$$

Where H denotes the set of HIV genome, and I represent the set of the *IGF1R* gene. Next, the CRISPR-Cas9 enzyme [5,6] is used to copy the HIV genome into the *IGF1R* gene of T cells. The set can be rewritten to:

$$I = \{\text{ENSE00003838363, gag, pol, env, ENSE00001316091}\}$$

The *IGF1R* gene is one of the known target genes of androgen receptor activation [7]. In mathematics, a function from a set X to a set Y is an assignment of an element of Y to each element of X . Hence, the process of transcription can be written in the following form:

$$f(x) = y \quad f(A) = I \quad A = \{\text{androgen, androgen receptor}\}$$

Where f is the function of RNA polymerase II, and A denotes the collection of androgen and its receptor. Then, the androgen and its receptor are injected into the T cells. After the *IGF1R* gene is transcribed by RNA polymerase II [8], the HIV will also 'wake

up' [9]. Python is one of the most popular programming languages [10], which can be used to write scripts to check the accuracy of mathematical formulas:

```

1  | #!/usr/bin/python3
2  | H = {'gag', 'pol', 'env'}
3  | I = {'ENSE00003838363', 'ENSE00001316091'}
4  | I.update(H)
5  | A = {'androgen', 'androgen receptor'}
6  | def f(x):
7  |     if x == A:
8  |         return I

```

The set H is defined to represent the HIV genome and the set I represents the *IGF1R* gene, then the `update()` method is used to insert H into I . Next, a set A is defined to represent androgen and its receptor, while $f(x)$ is defined to represent the function of RNA polymerase II, which returns the *IGF1R* gene applied on the set A . At last, $H \leq f(A)$ is printed to verify whether the virus is activated or not. As a result, the Python program returns True, which indicates that the dormant HIV infection is reawakened.

```

9  | print(H <= f(A)) #True

```

Can this possibly mean that the androgen reawakens the sleeping HIV? The answer is that the androgen reawakens the *IGF1R* gene that contains the HIV genome, not the retrovirus directly. In fact, even the Python program returns a result of False.

```

10 | print(H == f(A)) #False

```

It can be seen that the collection of elements returned by the method includes the HIV set, which doesn't mean that the two sets are equal. In mathematics, their relationship can be expressed as follows:

$$H \subseteq f(A)$$

$$H \neq f(A)$$

Several NIH-funded studies claim that AZD5582 can reawaken the sleeping HIV and SIV, but they also claim that the effectiveness rate is only at 42% [11,12,13]. Most importantly, the novel small-molecule IAP inhibitor AZD5582 was used for the treatment of cancer. It was reported to cause cIAP1 degradation, inducing apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro [14]. AZD5582 was involved in the process of transcription of cancer genes, and the genome it actually reawakens just happened to contain HIV genome, so it is a false reawakening.

2.2. Differentiating between the indirect and direct activation

Besides AZD5582, many studies claim that latency-reversing drugs can be used to reawaken the sleeping HIV, including Ciapavir [15], bryostatin-1 [16], disulfiram [17], ingenol-B [18], prostratin [19].



Figure 1. Latency-reversing drugs

What could be the mechanism behind this? In molecular biology, a base pair is a fundamental unit of double-stranded nucleic acids consisting of two nucleobases bound to each other by hydrogen bonds, such as adenine-thymine (AT) and guanine-cytosine (GC) [20]. Hydrogen bonds are usually formed between atoms that are electronically complementary, i.e., between a proton acceptor atom with a partial negative charge and an opposing proton atom with a partial positive charge [21].



Figure 2. Watson-Crick base pair

Therefore, in order to transfer the electromagnetic interaction [22], the latency-reversing drugs should also be matched with the corresponding nucleobases. Unfortunately, the atoms that constitute these drugs are completely different. Even if their atoms are all matched with corresponding nucleobases, e.g., an oxygen atom and a hydrogen atom as thymine, the formed sequences are still different and cannot match with the same genome of the same virus at the same time. In fact, disulfiram doesn't even have an oxygen atom, as shown in Fig. 3.




Figure 3. Disulfiram

More importantly, the author seeks to define which atom is the starting point and which is the ending point. Furthermore, the author tries to know how does RNA polymerase II read each atom and in what order. Since these drugs do not have regular patterns of structure, they cannot be directly identified by the RNA polymerase II. On the other hand, the one that has a fixed structure can be identified by the polymerase, e.g., the androgen receptor, which has amino acid sequences that can be sequentially read in a fixed order.

In addition, these drugs have completely different shapes and sizes, and if two atoms are far away from each other, then the electromagnetic interaction is negligible. The electromagnetic force that occurs between two electrically charged particles can be mathematically expressed according to Coulomb's law [23] as follows:

$$F = k_e \frac{q_1 q_2}{r^2} \qquad k_e = \frac{1}{4\pi\epsilon_0}$$

Where k_e is the Coulomb's constant, q denotes the signed magnitudes of the charge, r represents the distance between two charges, and ϵ_0 is the vacuum permittivity. It can be seen that when the distance is more than 1 nm, the electromagnetic force between two atoms will be less than 1% of the force at the distance of 0.1 nm. The androgen receptor, which is made up of hundreds of proteins, is much bigger than the latency-reversing drugs.

If the connection at the molecular level is magnified to the macro-level, it would be as if those scientists are trying to put different types of plugs into one completely mismatched receptacle. An example is illustrated in Fig. 4.




Figure 4. Drugs reawaken

In computer science, in order to make one receptacle match with different plugs, each of these plugs requires a unique adapter to convert the electromagnetic interaction. Similarly, the androgen is adapted by its receptor, and it is the androgen receptor that directly activates the *IGF1R* gene, not the androgen.

While these conclusions do not doubt the NIH-funded studies, the blame is on the RNA polymerase II. The one that made the mistake must be the polymerase, which has countless protein structures in a superposition and can automatically match with every latency-reversing drug, accurately converting the electromagnetic interaction without the receptors. It is worth mentioning that those latency-reversing drugs were also used for the treatment of cancer [24,25,26,27], just like AZD5582 [14].

2.3. The proposed model

It is well known that HIV recruits human uncharged tRNA to serve as the reverse transcription primer [28]. The HIV genome and *IGF1R* gene are both transcribed by RNA polymerase II [8,9]. The *IGF1R* gene is one of the known target genes of androgen receptor activation [7], and the androgen receptor is recruited by RNA polymerase II [29]. A promoter is a DNA sequence that leads RNA polymerase II to the correct initiation site [30]. Adenine, cytosine and guanine are found in both RNA and DNA, uracil and thymine are both bound to adenine via two hydrogen bonds [31], and tRNA serves as the physical link between the mRNA and the amino acid sequences of proteins [32].

Availability and requirements

Datasets were produced by python3, tool available at <https://github.com/rheast/genome>. Nucleotides were downloaded from NCBI <https://www.ncbi.nlm.nih.gov/nucleotide/>. Samples nucleotides correspond to accession numbers: NC_001436, NC_001488, NC_000858, NC_001815, NC_001802, NC_001722, NC_001549 and NC_001482.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

References

1. National Institute of Health. "What is a Latent HIV Reservoir?" NIH. 2021 August 4. hivinfo.nih.gov/understanding-hiv/fact-sheet/what-latent-hiv-reservoir
2. Siliciano RF. "Drugs fail to reawaken dormant HIV infection." Johns Hopkins Medicine. 2014 March 24. [hopkinsmedicine.org/news/media/releases/drugs_fail_to_reawaken_dormant_hiv_infection](https://www.hopkinsmedicine.org/news/media/releases/drugs_fail_to_reawaken_dormant_hiv_infection)
3. Seibert SA, Howell CY, et al. "Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1)." *Molecular biology and evolution*. 1995 Sep 1; 12(5):803-13. doi: [10.1093/oxfordjournals.molbev.a040257](https://doi.org/10.1093/oxfordjournals.molbev.a040257)
4. Abbott AM, Bueno R, et al. "Insulin-like growth factor I receptor gene structure." *Journal of Biological Chemistry*. 1992 May 25; 267(15):10759-63. doi: [10.1016/S0021-9258\(19\)50083-7](https://doi.org/10.1016/S0021-9258(19)50083-7)
5. Zhang F, Wen Y, Guo X. "CRISPR/Cas9 for genome editing: progress, implications and challenges." *Human molecular genetics*. 2014 Sep 15; 23(R1):R40-6. doi: [10.1093/hmg/ddu125](https://doi.org/10.1093/hmg/ddu125)
6. Bak RO, Gomez-Ospina N, Porteus MH. "Gene editing on center stage." *Trends in Genetics*. 2018 Aug 1; 34(8):600-11. doi: [10.1016/j.tig.2018.05.004](https://doi.org/10.1016/j.tig.2018.05.004)
7. Pandini G, Mineo R, et al. "Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells." *Cancer research*. 2005 Mar 1; 65(5):1849-57. doi: [10.1158/0008-5472.CAN-04-1837](https://doi.org/10.1158/0008-5472.CAN-04-1837)
8. Aleksic T, Gray N, et al. "Nuclear IGF1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage." *Cancer research*. 2018 Jul 1; 78(13):3497-509. doi: [10.1158/0008-5472.CAN-17-3498](https://doi.org/10.1158/0008-5472.CAN-17-3498)
9. Ott M, Geyer M, Zhou Q. "The control of HIV transcription: keeping RNA polymerase II on track." *Cell host & microbe*. 2011 Nov 17; 10(5):426-35. doi: [10.1016/j.chom.2011.11.002](https://doi.org/10.1016/j.chom.2011.11.002)
10. Van Rossum G. "An introduction to Python for UNIX/C programmers." *Proc. of the NLUUG najaarsconferentie*. Dutch UNIX users group. 1993 Nov:38.
11. National Institute of Health. "NIH-supported scientists reverse HIV and SIV latency in two animal models." NIH. 2020 January 22.
12. Nixon CC, Mavigner M, et al. "Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo." *Nature*. 2020 Feb; 578(7793):160-5. doi: [10.1038/s41586-020-1951-3](https://doi.org/10.1038/s41586-020-1951-3)
13. McBrien JB, Mavigner M, et al. "Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells." *Nature*. 2020 Feb; 578(7793):154-9. doi: [10.1038/s41586-020-1946-0](https://doi.org/10.1038/s41586-020-1946-0)
14. Hennessy EJ, Adam A, et al. "Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)." *Journal of medicinal chemistry*. 2013 Dec 27; 56(24):9897-919. doi: [10.1021/jm401075x](https://doi.org/10.1021/jm401075x)
15. Pache L, Marsden MD, et al. "Pharmacological activation of non-canonical NF- κ B signaling activates latent HIV-1 reservoirs in vivo." *Cell Reports Medicine*. 2020 Jun 23; 1(3):100037. doi: [10.1016/j.xcrm.2020.100037](https://doi.org/10.1016/j.xcrm.2020.100037)
16. Bullen CK, Laird GM, et al. "New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo." *Nature medicine*. 2014 Apr; 20(4):425-9. doi: [10.1038/nm.3489](https://doi.org/10.1038/nm.3489)
17. Spivak AM, Andrade A, et al. "A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy." *Clinical infectious diseases*. 2014 Mar 15; 58(6):883-90. doi: [10.1093/cid/cit813](https://doi.org/10.1093/cid/cit813)
18. Darcis G, Kula A, et al. "An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatins-1+ JQ1 and ingenol-B+ JQ1 to potentially reactivate viral gene expression." *PLoS pathogens*. 2015 Jul 30; 11(7):e1005063. doi: [10.1371/journal.ppat.1005063](https://doi.org/10.1371/journal.ppat.1005063)
19. Laird GM, Bullen CK, et al. "Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations." *The Journal of*

- clinical investigation. 2015 May 1; 125(5):1901-12. doi: [10.1172/JCI80142](https://doi.org/10.1172/JCI80142)
20. Watson JD, Crick FH. "Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid." *Nature*. 1953 Apr; 171(4356):737-8. doi: [10.1038/171737a0](https://doi.org/10.1038/171737a0)
 21. van der Lubbe SC, Fonseca Guerra C. "The nature of hydrogen bonds: A delineation of the role of different energy components on hydrogen bond strengths and lengths." *Chemistry—An Asian Journal*. 2019 Aug 16; 14(16):2760-9. doi: [10.1002/asia.201900717](https://doi.org/10.1002/asia.201900717)
 22. Maxwell JC. "VIII. A dynamical theory of the electromagnetic field." *Philosophical transactions of the Royal Society of London*. 1865 Dec 31; (155):459-512.
 23. Coulomb CA. "Second mémoire sur l'électricité et le magnétisme". *Histoire de l'Académie Royale des Sciences*. 1785; 578-611.
 24. Lin J, Haffner MC, et al. "Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth." *The Prostate*. 2011 Mar 1; 71(4):333-43. doi: [10.1002/pros.21247](https://doi.org/10.1002/pros.21247)
 25. Philip PA, Rea D, et al. "Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo." *Journal of the National Cancer Institute*. 1993 Nov 17; 85(22):1812-8. doi: [10.1093/jnci/85.22.1812](https://doi.org/10.1093/jnci/85.22.1812)
 26. Silva VA, Rosa MN, et al. "Cytotoxic activity of semi-synthetic ingenol derived from *Euphorbia tirucalli* on a large panel of human cancer cell lines." 2013; e13559-e13559. doi: [10.1200/jco.2013.31.15_suppl.e13559](https://doi.org/10.1200/jco.2013.31.15_suppl.e13559)
 27. Alotaibi D, Amara S, et al. "Potential anticancer effect of prostratin through SIK3 inhibition." *Oncology Letters*. 2018 Mar 1; 15(3):3252-8. doi: [10.3892/ol.2017.7674](https://doi.org/10.3892/ol.2017.7674)
 28. Duchon AA, St. Gelais C, et al. "HIV-1 exploits a dynamic multi-aminoacyl-tRNA synthetase complex to enhance viral replication." *Journal of virology*. 2017 Oct 13; 91(21):e01240-17. doi: [10.1128/JVI.01240-17](https://doi.org/10.1128/JVI.01240-17)
 29. Wang Q, Carroll JS, Brown M. "Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking." *Molecular cell*. 2005 Sep 2; 19(5):631-42. doi: [10.1016/j.molcel.2005.07.018](https://doi.org/10.1016/j.molcel.2005.07.018)
 30. Smale ST, Kadonaga JT. "The RNA polymerase II core promoter." *Annual review of biochemistry*. 2003 Jul; 72(1):449-79. doi: [10.1146/annurev.biochem.72.121801.161520](https://doi.org/10.1146/annurev.biochem.72.121801.161520)
 31. Minchin S, Lodge J. "Understanding biochemistry: structure and function of nucleic acids." *Essays in biochemistry*. 2019 Oct 16; 63(4):433-56. doi: [10.1042/EBC20180038](https://doi.org/10.1042/EBC20180038)
 32. Weiner AM, Maizels N. "tRNA-like structures tag the 3' ends of genomic RNA molecules for replication: implications for the origin of protein synthesis." *Proceedings of the National Academy of Sciences*. 1987 Nov 1; 84(21):7383-7. doi: [10.1073/pnas.84.21.7383](https://doi.org/10.1073/pnas.84.21.7383)
 33. Bohl CE, Miller DD, et al. "Structural basis for accommodation of nonsteroidal ligands in the androgen receptor." *Journal of Biological Chemistry*. 2005 Nov 11; 280(45):37747-54. doi: [10.1074/jbc.M507464200](https://doi.org/10.1074/jbc.M507464200)
 34. Jishage M, Yu X, et al. "Architecture of Pol II (G) and molecular mechanism of transcription regulation by Gdown1." *Nature structural & molecular biology*. 2018 Sep; 25(9):859-67. doi: [10.1038/s41594-018-0118-5](https://doi.org/10.1038/s41594-018-0118-5)
 35. Westhof E, Dumas P, Moras D. "Restrained refinement of two crystalline forms of yeast aspartic acid and phenylalanine transfer RNA crystals." *Acta Crystallographica Section A: Foundations of Crystallography*. 1988 Mar 1; 44(2):112-24. doi: [10.1107/S010876738700446X](https://doi.org/10.1107/S010876738700446X)
 36. Hu WS, Temin HM. "Retroviral recombination and reverse transcription." *Science*. 1990 Nov 30; 250(4985):1227-33. doi: [10.1126/science.1700865](https://doi.org/10.1126/science.1700865)
 37. Negroni M, Buc H. "Copy-choice recombination by reverse transcriptases: reshuffling of genetic markers mediated by RNA chaperones." *Proceedings of the National Academy of Sciences*. 2000 Jun 6; 97(12):6385-90. doi: [10.1073/pnas.120520497](https://doi.org/10.1073/pnas.120520497)
 38. Petropoulos C. "Retroviral taxonomy, protein structures, sequences, and genetic maps." *Retroviruses*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 1997; 757-805.
 39. Shimotohno K, Takahashi Y, et al. "Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene." *Proceedings of the National Academy of Sciences*. 1985 May 1; 82(10):3101-5. doi: [10.1073/pnas.82.10.3101](https://doi.org/10.1073/pnas.82.10.3101)
 40. Saksena NK, Hervé V, et al. "Sequence and phylogenetic analyses of a new STLV-I from a naturally infected tantalus monkey from Central Africa." *Virology*. 1993 Jan 1; 192(1):312-20. doi: [10.1006/viro.1993.1035](https://doi.org/10.1006/viro.1993.1035)
 41. Van Brussel M, Salemi M, et al. "The Simian T-Lymphotropic Virus STLV-PP1664 from *Pan paniscus* Distinctly Related to HTLV-2 but Differs in Genomic Organization." *Virology*. 1998 Apr 10; 243(2):366-79. doi: [10.1006/viro.1998.9075](https://doi.org/10.1006/viro.1998.9075)
 42. Martoglio B, Graf R, Dobberstein B. "Signal peptide fragments of preprolactin and HIV-1 p-gp160 interact with calmodulin." *The EMBO journal*. 1997 Nov 15; 16(22):6636-45. doi: [10.1093/emboj/16.22.6636](https://doi.org/10.1093/emboj/16.22.6636)
 43. Kirchhoff F, Jentsch KD, et al. "A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses." *Virology*. 1990 Jul 1; 177(1):305-11. doi: [10.1016/0042-6822\(90\)90484-9](https://doi.org/10.1016/0042-6822(90)90484-9)
 44. Fomsgaard A, Hirsch VM, et al. "A highly divergent proviral DNA clone of SIV from a distinct species of African green monkey." *Virology*. 1991 May 1; 182(1):397-402. doi: [10.1016/0042-6822\(91\)90689-9](https://doi.org/10.1016/0042-6822(91)90689-9)
 45. Olmsted RA, Hirsch VM, et al. "Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses." *Proceedings of the National Academy of Sciences*. 1989 Oct 1; 86(20):8088-92. doi: [10.1073/pnas.86.20.8088](https://doi.org/10.1073/pnas.86.20.8088)